SWITCH BETWEEN REFERENCE ETANERCEPT (ETN) AND GP2015, AN ETANERCEPT BIOSIMILAR, DID NOT IMPACT EFFICACY AND SAFETY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: 48-WEEK RESULTS FROM THE PHASE 3 EQUIRA STUDY

被引：5
|
作者：
Matucci-Cerinic, M. [1 ]
Schulze-Koops, H. [2 ]
Buch, M. [3 ]
Kavanaugh, A. [4 ]
Allanore, Y. [5 ]
Kucharz, E. J. [6 ]
Babic, G. [7 ]
机构：
[1] Univ Florence, Florence, Italy
[2] Ludwig Maximillans Univ, Munich, Germany
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[5] Paris Descartes Univ, Cochin Hosp, Paris, France
[6] Med Univ Silesia, Katowice, Poland
[7] Hexal AG, Holzkirchen, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.1368
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0129
引用
收藏
页码：609 / 609
页数：1
相关论文
共 50 条
  • [41] Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial
    Suh, Chang-Hee
    Yoo, Dae Hyun
    Berrocal Kasay, Alfredo
    Chalouhi El-Khouri, Elia
    Cons Molina, Francisco Fidenci
    Shesternya, Pavel
    Miranda, Pedro
    Medina-Rodriguez, Francisco G.
    Wiland, Piotr
    Jeka, Slawomir
    Chavez-Corrales, Jose
    Linde, Thomas
    Hrycaj, Pawel
    Abello-Banfi, Mauricio
    Hospodarskyy, Ihor
    Jaworski, Janusz
    Piotrowski, Mariusz
    Brzosko, Marek
    Krogulec, Marek
    Shevchuk, Sergii
    Calvo, Armando
    Andersone, Daina
    Park, Won
    Shim, Seung Cheol
    Lee, Sang Joon
    Lee, Sung Young
    BIODRUGS, 2019, 33 (01) : 79 - 91
  • [42] Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial
    Chang-Hee Suh
    Dae Hyun Yoo
    Alfredo Berrocal Kasay
    Elia Chalouhi El-Khouri
    Francisco Fidenci Cons Molina
    Pavel Shesternya
    Pedro Miranda
    Francisco G. Medina-Rodriguez
    Piotr Wiland
    Slawomir Jeka
    Jose Chavez-Corrales
    Thomas Linde
    Pawel Hrycaj
    Mauricio Abello-Banfi
    Ihor Hospodarskyy
    Janusz Jaworski
    Mariusz Piotrowski
    Marek Brzosko
    Marek Krogulec
    Sergii Shevchuk
    Armando Calvo
    Daina Andersone
    Won Park
    Seung Cheol Shim
    Sang Joon Lee
    Sung Young Lee
    BioDrugs, 2019, 33 : 79 - 91
  • [43] Efficacy and safety of ixekizumab compared to etanercept or placebo treatment of patients with moderate-to-severe plaque psoriasis and palmoplantar involvement over a 60-week dosing period: results from UNCOVER-3, a Phase 3 trial
    Warren, R. B.
    Morita, A.
    Menter, A.
    Duffin, K. Callis
    Langley, R.
    Amato, D.
    Dennehy, E. B.
    Kerr, L. N.
    Shrom, D.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 78 - 79
  • [44] Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study
    Zubrzycka-Sienkiewicz, Anna
    Klama, Kamilla
    Ullmann, Martin
    Petit-Frere, Corinne
    Baker, Peter
    Monnet, Joelle
    Illes, Andras
    RMD OPEN, 2024, 10 (01):
  • [45] Comparison of the Efficacy, Safety and Immunogenicity of a Proposed Biosimilar MSB11456 with Tocilizumab Reference Product in Moderate-to-Severe Rheumatoid Arthritis: Results of a Randomized Double-Blind Study
    Zubrzycka-Sienkiewicz, Anna
    Misterska-Skora, Maria
    Socik-Pojawa, Malgorzata
    Klama, Kamilla
    Ullman, Martin
    Petit-Frere, Corinne
    Illes, Andras
    Baker, Peter
    Monnet, Joelle
    Morais, Jeremy
    Brzezicki, Jan
    RHEUMATOLOGY, 2024, 63
  • [46] EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY
    Bird, Paul
    Smolen, Josef S.
    Xie, Li
    Jia, Bochao
    Taylor, Peter C.
    Burmester, Gerd
    Tanaka, Yoshiya
    Elias, Ayesha
    Cardoso, Anabela
    Ortmann, Rob
    Walls, Chad
    Dougados, Maxime
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 23 - 23
  • [47] COMPARISON OF THE EFFICACY, SAFETY AND IMMUNOGENICITY OF A PROPOSED BIOSIMILAR MSB11456 WITH TOCILIZUMAB REFERENCE PRODUCT IN MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A RANDOMIZED DOUBLE-BLIND STUDY
    Zubrzycka-Sienkiewicz, Anna
    Misterska-Skora, Maria
    Socik-Pojawa, Malgorzata
    Klama, Kamilla
    Ullman, Martin
    Petit-Frere, Corinne
    Illes, Andras
    Baker, Peter
    Monnet, Joelle
    Morais, Jeremy
    Brzezicki, Jan
    RHEUMATOLOGY, 2024, 63
  • [48] Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
    Smolen, Josef S.
    Xie, Li
    Jia, Bochao
    Taylor, Peter C.
    Burmester, Gerd
    Tanaka, Yoshiya
    Elias, Ayesha
    Cardoso, Anabela
    Ortmann, Rob
    Walls, Chad
    Dougados, Maxime
    RHEUMATOLOGY, 2021, 60 (05) : 2256 - 2266
  • [49] EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY
    Smolen, J. S.
    Xie, L.
    Jia, B.
    Taylor, P. C.
    Burmester, G. R.
    Tanaka, Y.
    Elias, A.
    Cardoso, A.
    Ortmann, R.
    Walls, C.
    Dougados, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1012 - 1012
  • [50] Ixekizumab impact on itch severity compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis
    Kimball, Alexa Boer
    Nikai, Enkeleida
    Zhu, Baojin
    Carlier, Hilde
    Yosipovitch, Gil
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S19 - S19
12345